用双特异性抗CD3xMUC16抗体和抗PD-1抗体治疗癌症的方法

本发明的方法包含向有需要的个体施用治疗有效量的特异性结合到程序性死亡1(PD-1)受体的抗体或其抗原结合片段以及治疗有效量的特异性结合粘蛋白16(MUC16)和CD3的双特异性抗体。 The present invention provides methods for treating, reducing the severity, or inhibiting the growth of cancer (e.g., ovarian cancer or pancreatic cancer). The methods of the present invention comprise admini...

Full description

Saved in:
Bibliographic Details
Format Patent
LanguageChinese
Published 23.05.2025
Subjects
CHEMISTRY
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
METALLURGY
ORGANIC CHEMISTRY
PEPTIDES
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Online AccessGet full text

Cover

More Information
Summary:本发明的方法包含向有需要的个体施用治疗有效量的特异性结合到程序性死亡1(PD-1)受体的抗体或其抗原结合片段以及治疗有效量的特异性结合粘蛋白16(MUC16)和CD3的双特异性抗体。 The present invention provides methods for treating, reducing the severity, or inhibiting the growth of cancer (e.g., ovarian cancer or pancreatic cancer). The methods of the present invention comprise administering to a subject in need thereof a therapeutically effective amount of an antibody or antigen-binding fragment thereof that specifically binds to programmed death 1 (PD-1) receptor in combination with a therapeutically effective amount of a bispecific antibody that specifically binds Mucin 16 (MUC16) and CD3.
Bibliography:Application Number: CN20198040564